GSK introduces cardiology drug

GlaxoSmithKline Pharmaceuticals (GSK) has strengthened its portfolio of cardiology drugs in Sri Lanka with the introduction of Benitec the original Olmesartan Medoxomil developed by Daiichi-Sankyo, for the treatment of hypertension.

Proven to reduce systolic blood pressure by -12 mmHg over 24 hours and also provide blood pressure (BP) control for the early morning BP Surge1 (Ref. Fabia MJ et al. Journal of Hypertension 2007, 25:1327-1336), Benitec is available for oral use as a film-coated tablet, a company official said.

Managing Director, GSK Pharmaceuticals, Sri Lanka, Stuart Chapman said, "The launch of Benitec in Sri Lanka following its registration with the Cosmetics, Devices and Drugs Regulatory Authority will make an important contribution to the management of hypertension in the target patient group. As is the case with all pharmaceuticals manufactured by or for GSK, quality of product and packaging conform to highest global standards."Benitec is the third cardiology drug introduced recently by GSK to the local market.

The others are two synthetic lipid-lowering agents for oral administration for patients with elevated cholesterol levels.